缬沙坦对扩张型心肌病大鼠炎症因子表达的影响
2011年3月25日 13:27 作者:尹春阳【摘要】 探讨血管紧张素Ⅱ1型(AT1)受体阻滞剂缬沙坦对扩张型心肌病(DCM)大鼠炎症因子表达的影响及意义。方法: 腹腔注射多柔比星建立SD大鼠DCM模型。随机分为DCM模型组(M组, n=11)、缬沙坦组(V组, n=10)、正常对照组(C组, n=10),V组予以缬沙坦30 mg·kg-1·d-1,C组和M组予以生理盐水灌胃,8周后行心脏超声和血流动力学检测,放免法检测血清TNF?α,IL?6,IL?1β浓度,测定心室质量及指数,观察心肌病理改变,测定心肌胶原含量(CVF)。结果: 与C组相比,M组左室内径、心室质量及指数显著增加(P<0.05),心功能显著降低(P<0.05),血清TNF?α,IL?6,IL?1β浓度和心肌胶原含量显著升高(P<0.05)。缬沙坦可以显著降低DCM大鼠血清TNF?α,IL?6,IL?1β水平和心肌胶原含量(P<0.05),缩小左室内径、降低心室质量及指数(均P<0.05),改善心功能(P<0.05)。结论: 缬沙坦可以通过降低DCM炎症因子表达,部分逆转心室重塑,改善心功能。 快速论文发表【关键词】 多柔比星 缬沙坦 扩张型心肌病 细胞因子
[Abstract] Objective: To investigate the changes of inflammatory cytokines in rats with dilated cardiomyopathy(DCM)and whether angiotensinⅡtype1(AT1)receptor blocker, valsartan, has a protective effect by influencing inflammatory cytokines. Methods: Models of DCM were established by adriamycin injected via intraperitonealy in SD rats. Rats were divided randomly into 3 groups as follows: DCM group(group M, n=11), valsartan group(group V, n=10), control group(group C, n=10). Valsartan was administered by daily gavage at a dose of 30 mg·kg-1·d-1 in group V for 8 weeks. Physiological saline was administered in group C and group M. Hemodynamics and echocardiographic measurents were obtained after 8 weeks. Concentration of TNF?α,IL?6,IL?1β in serum was determined by method of radioimmunoassay. ventricle was weighed and weight index was measured. Histopathological characteristics were observed by HE and VG dyeing. Collagen volume fraction(CVF)was calculated. Results: Compared with group C, the diameter of left Ventricle in group M was significantly extended, which was attenuated in group V(P<0.05); ventricular weight and index were increased in group M and significantly reduced by valsartan treatment(P<0.05); left ventricular contractile fuction in group M is significantly decreased, which was partly nomalized by valsartan(P<0. 05); concentration of TNF?α,IL?6,IL?1β in serum and cardiac collagen volume fraction was significantly increased in group M and attenuated by valsartan treatment(P<0.05). Conclusion: Treatment with valsartan can attenuate ventricular remodeling and partly normalize contractile function by decreasing the expression of TNF?α,IL?6,IL?1β in rats with dilated cardiomyopathy.
[Key words] adriamycin; valsartan; dilated cardiomyopathy; cytokine
扩张型心肌病(dilated cardiomyopathy, DCM)是充血性心力衰竭(CHF)的重要原因之一。近年来,有研究者发现,TNF?α,IL?6,IL?1β等炎症因子与心力衰竭的发生、发展及预后密切相关[1]。本研究旨在观察血管紧张素Ⅱ1型(AT1)受体阻滞剂缬沙坦对DCM心力衰竭大鼠炎症因子表达的影响,探讨AT1受体阻滞剂治疗DCM心力衰竭的新机制。快速论文发表
1 材料和方法
1.1 材 料
1.1.1 实验动物 健康成年雄性SD大鼠,40只,体质量(254±27)g,由江苏大学实验动物中心提供。
1.1.2 试剂 多柔比星由浙江海正药业股份有限公司生产;氯胺酮由江苏恒瑞医药有限公司生产;缬沙坦由北京诺华制药有限公司馈赠;TNF?α,IL?6,IL?1β放射免疫试剂盒,北京北方生物技术研究所产品;VG染色试剂盒,福州迈新生物技术开发有限公司产品。